NASDAQ: NVAXNovavax Inc Stock
$9.35+0.12 (+1.3%)
Updated Sep 16, 2026
NVAX Price
$9.35
Fair Value Price
N/A
Market Cap
$1.54B
52 Week Low
$6.20
52 Week High
$11.97
P/E
-6.15x
P/B
-8.09x
P/S
3.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$413.80M
Earnings
-$247.73M
Gross Margin
78.6%
Operating Margin
-53.99%
Profit Margin
-59.9%
Debt to Equity
-6.01
Operating Cash Flow
-$37M
Beta
1.8
Next Earnings
Nov 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
NVAX Overview
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NVAX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NVAX
Ranked#217 of 461
Ranked#217 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.39 | A | |
| $42.21 | A | |
| $111.81 | A |
Be the first to know about important NVAX news, forecast changes, insider trades & much more!
NVAX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NVAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVAX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVAX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
NVAX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more NVAX due diligence checks available for Premium users.
Valuation
NVAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.15x
Industry
9.99x
Market
44.18x
NVAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.09x
Industry
5.23x
NVAX's financial health
Profit margin
Revenue
$56.7M
Net Income
-$53.4M
Profit Margin
-94.2%
NVAX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NVAX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$955.6M
Liabilities
$1.1B
Debt to equity
-6.01
NVAX's short-term assets ($771.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVAX's long-term liabilities ($815.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVAX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NVAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$72.8M
Investing
$34.9M
Financing
$1.2M
NVAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NVAX vs Biotech Stocks
Novavax Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.